These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28074150)

  • 1. Colorectal cancer mortality 10 years after a single round of guaiac faecal occult blood test (gFOBT) screening: experiences from a Danish screening cohort.
    Bjerrum A; Andersen O; Fischer A; Lindebjerg J; Lynge E
    BMJ Open Gastroenterol; 2016; 3(1):e000120. PubMed ID: 28074150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of colorectal cancer after negative colonoscopy in a Danish gFOBT screening cohort.
    Bjerrum A; Andersen O; Fischer A; Lindebjerg J; Lynge E
    Int J Cancer; 2017 Aug; 141(3):503-511. PubMed ID: 28463410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cause of Death, Mortality and Occult Blood in Colorectal Cancer Screening.
    Kaalby L; Al-Najami I; Deding U; Berg-Beckhoff G; Steele RJC; Kobaek-Larsen M; Shaukat A; Rasmussen M; Baatrup G
    Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.
    Zorzi M; Fedeli U; Schievano E; Bovo E; Guzzinati S; Baracco S; Fedato C; Saugo M; Dei Tos AP
    Gut; 2015 May; 64(5):784-90. PubMed ID: 25179811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
    Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
    Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Likely effect of adding flexible sigmoidoscopy to the English NHS Bowel Cancer Screening Programme: impact on colorectal cancer cases and deaths.
    Geurts SM; Massat NJ; Duffy SW
    Br J Cancer; 2015 Jun; 113(1):142-9. PubMed ID: 26110973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
    Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
    Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland.
    Pitkäniemi J; Seppä K; Hakama M; Malminiemi O; Palva T; Vuoristo MS; Järvinen H; Paimela H; Pikkarainen P; Anttila A; Elovainio L; Hakulinen T; Karjalainen S; Pylkkänen L; Rautalahti M; Sarkeala T; Vertio H; Malila N
    BMJ Open Gastroenterol; 2015; 2(1):e000034. PubMed ID: 26462283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.
    Shuhaibar M; Walsh C; Lindsay F; Lee N; Walsh P; O'Gorman P; Boran G; McLoughlin R; Qasim A; Breslin N; Ryan B; O'Connor H; O'Morain C
    Ir J Med Sci; 2011 Mar; 180(1):103-8. PubMed ID: 20953981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised study of screening for colorectal cancer with faecal-occult-blood test.
    Kronborg O; Fenger C; Olsen J; Jørgensen OD; Søndergaard O
    Lancet; 1996 Nov; 348(9040):1467-71. PubMed ID: 8942774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing participation in colorectal cancer screening: results from a cluster randomized trial of directly mailed gFOBT kits to previous nonresponders.
    Tinmouth J; Patel J; Austin PC; Baxter NN; Brouwers MC; Earle C; Levitt C; Lu Y; Mackinnon M; Paszat L; Rabeneck L
    Int J Cancer; 2015 Mar; 136(6):E697-703. PubMed ID: 25195923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guaiac faecal occult blood screening in individuals younger than 50 years of age.
    Zalts R; Moadi Z; Avizohar O; Leiba R; Half E; Karban A
    Eur J Cancer Prev; 2017 May; 26(3):189-194. PubMed ID: 27167151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.
    Massat NJ; Moss SM; Halloran SP; Duffy SW
    J Med Screen; 2013; 20(3):125-48. PubMed ID: 24197771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.